Pharmaceuticals & Biotechnology
OXB is a specialist contract development and manufacturing organisation for cell and gene therapies. It develops and manufactures viral vectors for pharmaceutical and biotechnology customers from facilities in the UK, France and United States.
Process development, analytical services, GMP manufacturing and commercial supply of lentiviral, AAV, adenoviral and other viral vectors used in cell and gene therapies.
Global pharmaceutical and biotechnology companies developing clinical and commercial cell and gene therapies, with manufacturing operations in Europe and the United States.
New client wins, growth of contracted backlog, progression of therapies into late-stage and commercial use, capacity utilisation, operational efficiency and expansion of US manufacturing.
Client programme delays or cancellations, biotech funding conditions, customer concentration, facility ramp-up and GMP execution, regulatory requirements, cash usage, competition and foreign exchange.
7 August 2026: OXB cut FY2026 revenue guidance to £180-200m after client-order deferrals and a six-month delay to operational readiness at its Durham, North Carolina site. H1 revenue still rose about 9% to c.£80m, 17 new clients were signed and the backlog reached c.£193m; 2027 revenue-growth guidance of 25-30% and double-digit EBITDA margins was retained.
OXB does not currently pay a dividend. The Group is prioritising investment in capacity and growth while building sustainable profitability, so cash returns are unlikely to be a near-term feature unless the capital-allocation policy changes.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.